Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2023; 13(7):2057-2071. doi:10.7150/thno.78915 This issue Cite

Research Paper

Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer

Jordan M. White1,2, Nicholas Ramos1, Allen-Dexter Saliganan1, Joon-Yong Chung3, Meghan Bell3, Jacob Lindquist1,2, Kayla Conner1,2, Wendy N. Wiesend5, Michael Schopperle4, Steve M. Patrick1, Seongho Kim1, Elisabeth I. Heath1, Freddy E. Escorcia3, Nerissa T. Viola1✉

1. Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201
2. Cancer Biology Graduate Program, Wayne State University, School of Medicine, Detroit, MI 48201
3. Molecular Imaging Branch, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
4. Department of Anatomic Pathology, Beaumont Health System, Royal Oak, MI 48073
5. Curemeta, LLC, Boston, MA 02210

✉ Corresponding author: Nerissa T. Viola, Ph.D. 4100 John R Street, Detroit, MI 48201. Tel #: (313)576-8309; Fax #: (313)5768928; violanorg

Citation:
White JM, Ramos N, Saliganan AD, Chung JY, Bell M, Lindquist J, Conner K, Wiesend WN, Schopperle M, Patrick SM, Kim S, Heath EI, Escorcia FE, Viola NT. Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics 2023; 13(7):2057-2071. doi:10.7150/thno.78915. https://www.thno.org/v13p2057.htm
Other styles

File import instruction

Abstract

Graphic abstract

Purpose: TRA-1-60 (TRA) is an established transcription factor of embryonic signaling and a well-known marker of pluripotency. It has been implicated in tumorigenesis and metastases, is not expressed in differentiated cells, which makes it an appealing biomarker for immunopositron emission tomography (immunoPET) imaging and radiopharmaceutical therapy (RPT). Herein, we explored the clinical implications of TRA in prostate cancer (PCa), examined the potential of TRA-targeted PET to specifically image TRA+ cancer stem cells (CSCs) and assessed response to the selective ablation of PCa CSCs using TRA-targeted RPT.

Experimental Design: First, we assessed the relationship between TRA (PODXL) copy number alterations (CNA) and survival using publicly available patient databases. The anti-TRA antibody, Bstrongomab, was radiolabeled with Zr-89 or Lu-177 for immunoPET imaging and RPT in PCa xenografts. Radiosensitive tissues were collected to assess radiotoxicity while excised tumors were examined for pathologic treatment response.

Results: Patients with tumors having high PODXL CNA exhibited poorer progression-free survival than those with low PODXL, suggesting that it plays an important role in tumor aggressiveness. TRA-targeted immunoPET imaging specifically imaged CSCs in DU-145 xenografts. Tumors treated with TRA RPT exhibited delayed growth and decreased proliferative activity, marked by Ki-67 immunohistochemistry. Aside from minor weight loss in select animals, no significant signs of radiotoxicity were observed in the kidneys or livers.

Conclusions: We successfully demonstrated the clinical significance of TRA expression in human PCa, engineered and tested radiotheranostic agents to image and treat TRA+ prostate CSCs. Ablation of TRA+ CSCs blunted PCa growth. Future studies combining CSC ablation with standard treatment will be explored to achieve durable responses.

Keywords: TRA-1-60, prostate cancer stem cells, immunoPET imaging, Lutetium-177, radionuclide therapy

Citation styles

APA
White, J.M., Ramos, N., Saliganan, A.D., Chung, J.Y., Bell, M., Lindquist, J., Conner, K., Wiesend, W.N., Schopperle, M., Patrick, S.M., Kim, S., Heath, E.I., Escorcia, F.E., Viola, N.T. (2023). Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics, 13(7), 2057-2071. https://doi.org/10.7150/thno.78915.

ACS
White, J.M.; Ramos, N.; Saliganan, A.D.; Chung, J.Y.; Bell, M.; Lindquist, J.; Conner, K.; Wiesend, W.N.; Schopperle, M.; Patrick, S.M.; Kim, S.; Heath, E.I.; Escorcia, F.E.; Viola, N.T. Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics 2023, 13 (7), 2057-2071. DOI: 10.7150/thno.78915.

NLM
White JM, Ramos N, Saliganan AD, Chung JY, Bell M, Lindquist J, Conner K, Wiesend WN, Schopperle M, Patrick SM, Kim S, Heath EI, Escorcia FE, Viola NT. Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics 2023; 13(7):2057-2071. doi:10.7150/thno.78915. https://www.thno.org/v13p2057.htm

CSE
White JM, Ramos N, Saliganan AD, Chung JY, Bell M, Lindquist J, Conner K, Wiesend WN, Schopperle M, Patrick SM, Kim S, Heath EI, Escorcia FE, Viola NT. 2023. Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics. 13(7):2057-2071.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use